Discuva Appoints Dr Ursula Ney to its Board of Directors
Discuva, the antibiotics drug discovery and development company today announced that Dr Ursula Ney, has been appointed to the Company’s board of Directors.
“As we drive our much-needed new antibiotics into the clinic, we are pleased Ursula is joining us with her strong track record in all aspects of drug development and outstanding leadership experience in the Biotech and Pharmaceutical industry. Ursula will bring complementary skills and strategic experience to the Discuva board and we look forward to working together”, commented David Williams, Chief Executive Officer of Discuva.
Ursula has more than thirty years’ experience in the pharmaceutical and biotech industry, twenty years in leadership roles in the Biotech sector including as an executive director on the Board of Celltech plc, Antisoma plc and most recently as CEO of Genkyotex SA. She has broad experience of drug development across a range of therapeutic areas as well as corporate and commercial strategy. Her early career was spent in Sandoz then Roche after obtaining a PhD in pharmacology from the Royal Free Hospital Medical School, London.
Discuva is a Cambridge, UK-based Drug Discovery Company discovering new antibiotics against highly drug-resistant pathogens, which is aiming to revolutionise the treatment of disease caused by bacterial infection. Discuva’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and allow their progression through to drugs with low clinical resistance, providing real solutions to the threat of global antibiotic resistance. Discuva’s drug pipeline is focused on providing therapeutics for currently untreatable hospital and community-based infections.For further information please contact:David Williams, Chief Executive Officer Email: email@example.com Tel: +44(0)1223 394200 Web: www.discuva.com Investors: New Wave Ventures LLP and staff